fda import alert glp-1 semaglutide tirzepatide green list creates "green list" to block unsafe imports FDA's green list cracks down – Pharmacovigilance Assessment of Compounded GLP-1

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Oral semaglutide is a groundbreaking FDA-approved medication designed for chronic weight management and belongs to the GLP-1 receptor agonists class

The exact mechanism isnt fully understood, but researchers believe the drug affects blood flow to the optic nerve, particularly in patients with existing cardiovascular risk factors

Studies indicate that increasing glutathione levels may improve nerve function and reduce pain in conditions like diabetic neuropathy (Oyama et al., 2010, Diabetes Care)

The peptide instead works through a distinct mechanism involving beta-3 adrenergic receptor modulation in adipose tissue, providing fat metabolism benefits through a completely different pathway than growth hormones receptor-mediated effects